1.44
0.07 (5.11%)
| Previous Close | 1.37 |
| Open | 1.34 |
| Volume | 1,969,777 |
| Avg. Volume (3M) | 5,483,930 |
| Market Cap | 312,861,600 |
| Price / Sales | 13.81 |
| Price / Book | 0.800 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Operating Margin (TTM) | -1,170,372.75% |
| Diluted EPS (TTM) | -1.32 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 21.50% |
| Current Ratio (MRQ) | 8.54 |
| Operating Cash Flow (TTM) | -200.30 M |
| Levered Free Cash Flow (TTM) | -99.13 M |
| Return on Assets (TTM) | -27.01% |
| Return on Equity (TTM) | -55.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Allogene Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.13 |
|
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 17.73% |
| % Held by Institutions | 77.84% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tpg Gp A, Llc | 31 Dec 2024 | 18,716,306 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (Canaccord Genuity, 872.22%) | Buy |
| Median | 9.00 (525.00%) | |
| Low | 5.00 (Citizens Capital Markets, 247.22%) | Buy |
| Average | 9.25 (542.36%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 1.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Mar 2025 | 8.00 (455.56%) | Buy | 1.69 |
| Canaccord Genuity | 14 Mar 2025 | 14.00 (872.22%) | Buy | 1.94 |
| Citizens Capital Markets | 14 Mar 2025 | 5.00 (247.22%) | Buy | 1.94 |
| RBC Capital | 14 Mar 2025 | 10.00 (594.44%) | Buy | 1.94 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |